REVANCE THERAPEUTICS, INC. By Chris Wack
Revance Therapeutics said Friday that the U.S. Centers for Medicare & Medicaid Services has assigned a permanent J-code for Daxxify, indicated for the treatment of cervical dystonia in adults.
J-Codes are product-specific reimbursement codes used by commercial insurance plans, Medicare, and other government payers and are intended to simplify reimbursement for providers and expand access for patients.
The Food and Drug Administration approved Daxxify for the treatment of cervical dystonia in August 2023.
The Phase 3 clinical study showed that Daxxify was shown to be effective, generally safe, and well tolerated across two dose groups.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
02-02-24 0831ET
